Work Area: Valuation

Latest content

Pfizer’s $2.3 billion spend on CD47 inhibitors shows how oncology IP continues to drive pharma deal-making

The acquisition of the cutting-edge haematology candidates is just the latest development in the booming immuno-oncology market

26 August 2021

Toyota’s self-driving haul from Lyft includes 100+ US patent assets

Patents change hands after Japanese carmaker buys Lyft’s self-driving tech for $550 million

23 August 2021

Japan’s corporate watchdog calls for high-level emphasis on intellectual property

Changes to the country’s corporate governance code encourage boards to pay more attention to IP strategy

18 August 2021

mRNA IP will be hot property beyond the pandemic

$3.2 billion Sanofi deal is unlikely to be the last as Big Pharma seeks to consolidate its position in the cutting-edge field

12 August 2021

Healthcare Royalty Partners’ $750 million IPO to be next milestone for a booming market

The company is hoping to raise cash to help expand its purchasing power when acquiring pharmaceuticals revenue streams

05 August 2021

Investor interest in IP is about more than big money verdicts, claims Ocean Tomo transactions chief

Ten-figure awards in the patent space have caught capital’s attention, says Ocean Tomo's Ryan Zurek, but so has the IP market’s resilience in the face of economic turbulence

04 August 2021

Biopharma M&A has fallen off a cliff – but IP owners in the sector have reasons to be cheerful

The number and value of acquisitions have both tumbled further than in the early months of 2020

20 July 2021

Singapore banking on regional IP rise and dispute resolution to cement its hub status

An update to the country’s strategy recognises that facilitating ASEAN's patenting development is key

19 July 2021

IAM insight panel analysis Q2  2021

Featured in Community Insight

Second quarter panels report finds a marked increase in negative views about the administration, but fewer covid concerns and signs of higher royalty and sales prices

01 July 2021

University and Big Pharma JV’s $145 million take-off is a big boost for tech transfer dealmaking

Apollo Therapeutics is an innovative biotech formed by three UK universities and three major companies, with a promising model for creating and monetising life sciences IP

29 June 2021

Get unlimited access to all IAM content